Total Assets
Stockholders' Equity
Cash & Equivalents
Long-Term Debt
Revenue trend
Balance Sheet
Income Statement
Per Share & Cash Flow
Insider activity
SEC fundamentals · as filed in 10-Q FY2026, period ended Mar 31, 2026 · updated Aug 29, 2026
as filed in 10-Q FY2026, period ended Mar 31, 2026 · View filings on EDGAR ↗
In its FY2026 report, Benitec Biopharma Inc. reported total assets of $187.0M, stockholders' equity of $183.3M, and revenue of $0. Every figure below is taken directly from Benitec Biopharma Inc.'s SEC filings: each links to the source document on EDGAR.
Revenue · FY2019–FY2024 · as reported
as of Mar 31, 2026 · 10-Q
10-Q (quarterly) · period ended Mar 31, 2026
10-Q (quarterly) · period ended Mar 31, 2026
| EPS (diluted) | $-0.24 | Earnings | source ↗ |
| EPS (basic) | $-0.24 | Earnings | source ↗ |
| Shares Outstanding | 34.4M | Entity | source ↗ |
| Cash from Operations | -$4.5M | Net | source ↗ |
| Cash from Financing | $506,000 | Net | source ↗ |
| Cash from Investing | -$15,000 | Net | source ↗ |
Form 4 open-market activity, last 180 days
No open-market Form 4 transactions filed in the last 180 days.
7 of 170 annual fact-keys were materially restated between filings: what Benitec Biopharma Inc. first reported differed from what it later filed. We keep every vintage of every annual figure, each keyed to its EDGAR accession.
See each original-vs-restated value, and query any company as of any past date, with the point-in-time API.
As-of fundamentals at any past date are on Free too, up to 10 lookups a day; Analyst removes that cap and adds the original-vs-restated detail behind the counts above, plus MCP access for your own agents, across the whole SEC universe.
Not investment advice. Figures are shown as filed with the SEC; see the EDGAR source links for the original documents. Data may lag the latest filing.